Ascentage Pharma Group International
AAPG | NASDAQ
$13.29
-$1.33 (-9.10%)
At close: Nov 16, 2026, 4:00 PM ET
$13.40
+$0.11 (+0.83%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Ascentage Pharma Group International Company Profile
Company profile explainedCompany Profile
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Key Executives
| Name | Position |
|---|---|
| Dajun Yang | Co-Founder, Chairman & Chief Executive Officer |
| Veet Misra | Chief Financial Officer |
| Chongdong Fu | Senior Vice President & Head of CMC |
| James Ziegler | Chief Commercial Officer |
| Jin Cao | Head of Finance |
| Ming Guo | Co-Founder |
| Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director |
| Thomas Joseph Knapp | Senior Vice President & General Counsel |
| Yifan Zhai | Chief Medical Officer |
| Yuly Chen | Senior Director of Investor Relations |
Ascentage Pharma Group International
| Country | China |
| IPO Date | Jan 24, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 767 |
| CEO | Dajun Yang |
Contact Details
Suzhou Industrial Park Suzhou,
JS 215000 China
Stock Details
| Ticker Symbol | AAPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002023311 |
| CUSIP Number | 04390B105 |
| ISIN Number | US04390B1052 |
| SIC Code | 2834 |
Recent News
- 1 day ago / globenewswire.comAscentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
- 12 days ago / globenewswire.comAscentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
- 14 days ago / globenewswire.comAscentage Pharma to Participate in Two Upcoming Investor Conferences in London
- 27 days ago / globenewswire.comAscentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
- 1 month ago / benzinga.comAscentage Pharma Stock Could More Than Double: Analyst
- 1 month ago / marketbeat.com3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- 1 month ago / marketbeat.com3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
- 3 months ago / seekingalpha.comAscentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
- 3 months ago / marketbeat.comAscentage Pharma Group International H1 Earnings Call Highlights
- 3 months ago / globenewswire.comAscentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Add to Watchlist
Select watchlists to add or remove AAPG